Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CFDA Accepts NDA for Hepatitis C Drug from Ascletis

publication date: Dec 28, 2016
Ascletis Pharma, a Hangzhou innovative drug company, reported that the CFDA accepted its new drug application for danoprevir, a direct acting agent for hepatitis C. The company said its triple drug regimen for hepatitis C produced a cure rate of more than 95% in China gene type I hepatitis C patients after only 12 weeks of treatment. Ascletis will publish the data from the trial next year at the Asia-Pacific Liver Disease Society meeting. According to Ascletis, the acceptance is a big step toward launching a domestically developed small molecule antiviral drug, a milestone for itself and China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital